Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2016. The document serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibility (PDMR) regarding the vesting of conditional share awards under the GlaxoSmithKline Share Value Plan (SVP) originally granted in 2013.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on equity compensation events rather than operational financial performance.
Material Changes
The material event reported is the vesting of awards on February 28, 2016, following the end of the restricted period for the 2013 SVP awards. The vesting was conditional on continued employment with the GlaxoSmithKline group.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly details the mechanics of the share vesting and the associated share prices on the business day prior to vesting (February 26, 2016): Ordinary Shares at £14.105 and ADS at US$39.14.
Important Facts for Investors
- Vesting Event: Awards made in 2013 vested on February 28, 2016.
- Shares Vested: Mr. N. Hirons vested 5,740 Ordinary Shares; Mrs. V. Whyte vested 13,070 Ordinary Shares.
- PDMR Status: Mr. Hirons was not a PDMR at the time of the 2013 grant but was appointed PDMR subsequently.
- Notification Date: The Company and PDMRs were advised of these transactions on February 29, 2016.
- Reference Price: The closing price of an Ordinary Share on February 26, 2016, was £14.105.